177Lu-DOTATATE联合PARP抑制剂奥拉帕利在生长抑素阳性肿瘤患者中可行:LuPARP I期试验结果
LuPARP I期试验纳入18例生长抑素受体阳性肿瘤患者,评估奥拉帕利联合标准剂量177Lu-DOTATATE的可行性与毒性。联合方案总体耐受良好,血小板减少为主要剂量限制性毒性,300 mg剂量组3例出现。作者推荐未来研究起始剂量为200 mg每日两次,视耐受可递增至300 mg每日两次。
要点
- 18例生长抑素受体阳性肿瘤患者接受177Lu-DOTATATE 7,400 MBq联合奥拉帕利50-300 mg每日两次。
- 血小板减少为主要剂量限制性毒性,300 mg剂量组3例出现。
- 其它毒性轻微,以低级别骨髓抑制、恶心和乏力为主。
核心结论
- 奥拉帕利联合177Lu-DOTATATE可行,毒性主要与血小板减少相关。
- 基于研究结果推荐未来研究起始剂量为200 mg每日两次,视患者耐受可递增至300 mg每日两次。
- 需要在更大规模随机试验中进一步评估该联合方案的临床疗效并优化给药策略。
研究设计与样本
- I期试验,共纳入18例生长抑素受体阳性肿瘤患者,多为胰腺或小肠神经内分泌肿瘤或不典型肺类癌。
- 患者接受标准剂量177Lu-DOTATATE(7,400 MBq)最多4个周期,联合奥拉帕利剂量递增(50-300 mg每日两次)。
- 主要目标为采用美国国家癌症研究所常见毒性标准5.0版评估毒性,次要目标包括至进展时间、总生存、缓解率和剂量学变量。
主要发现
- 奥拉帕利联合177Lu-DOTATATE总体耐受良好。
- 5例患者因进展、不依从或首次177Lu-DOTATATE输注后类癌危象而未完成4个周期。
- 在其余患者中,血小板减少为主要剂量限制性毒性,300 mg剂量组3例出现。
- 其它毒性轻微,以低级别骨髓抑制、恶心和乏力为主。
关键数值与推荐
- 177Lu-DOTATATE标准剂量为7,400 MBq,最多4个周期。
- 奥拉帕利剂量递增范围为50-300 mg每日两次。
- 毒性评估采用美国国家癌症研究所常见毒性标准5.0版。
- 推荐未来研究奥拉帕利起始剂量为200 mg每日两次,视耐受可递增至300 mg每日两次。
临床怎么用
- 作者推荐未来研究起始剂量为200 mg每日两次,视患者耐受可递增至300 mg每日两次。
- 作者认为需在更大规模随机试验中进一步评估该联合方案的临床疗效并优化给药策略。
局限性
- 5例患者因进展、不依从或首次177Lu-DOTATATE输注后类癌危象而未完成4个周期。
- 需要在更大规模随机试验中进一步评估该联合方案的临床疗效并优化给药策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This phase I trial aimed to assess the feasibility and toxicity of combining the poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib with 177Lu-DOTATATE in patients with somatostatin receptor-positive tumors, with the goal of enhancing treatment efficacy through the inhibition of tumor cell DNA repair mechanisms. Methods: Eighteen patients were enrolled, mostly with pancreatic or small intestinal neuroendocrine tumors or atypical lung carcinoids. Patients received a standard dose of 177Lu-DOTATATE (7,400 MBq) for up to 4 cycles, combined with escalating doses of olaparib (50-300 mg twice a day [BID]). The primary objective was to evaluate toxicity using National Cancer Institute Common Toxicity Criteria version 5.0. Secondary objectives included time to progression, overall survival, response rate, and dosimetry variables. Results: The combination of olaparib and 177Lu-DOTATATE was generally well tolerated. Five patients did not complete the 4 cycles because of progression, noncompliance, and carcinoid crisis after the first 177Lu-DOTATATE infusion. Among the remaining patients, thrombocytopenia was the primary dose-limiting toxicity, observed in 3 patients at the 300-mg dose level. Other toxicities were mild, predominantly low-grade bone marrow suppression, nausea, and fatigue. Conclusion: This study demonstrates that combining olaparib with 177Lu-DOTATATE is feasible, with toxicity primarily related to thrombocytopenia. On the basis of the findings, we recommend a starting dose of 200 mg BID for future studies, with the potential to escalate to 300 mg BID depending on patient tolerance. Further investigation in larger, randomized trials is warranted to assess the clinical efficacy of this combination and optimize dosing strategies.
引用
- Hallqvist A, Brynjarsdóttir E, Krantz T, et al. 177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial. J Nucl Med. 2025. PMID: 40015919. doi:10.2967/jnumed.124.268902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。